Compare CSW & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSW | TVTX |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | 2600 | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.3B |
| IPO Year | N/A | 2013 |
| Metric | CSW | TVTX |
|---|---|---|
| Price | $282.64 | $56.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | ★ $323.20 | $40.62 |
| AVG Volume (30 Days) | 126.9K | ★ 2.1M |
| Earning Date | 05-21-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.38% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.19 | $44.76 |
| Revenue Next Year | $19.04 | $35.51 |
| P/E Ratio | $40.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $230.45 | $15.03 |
| 52 Week High | $337.02 | $60.10 |
| Indicator | CSW | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.48 | 60.92 |
| Support Level | $268.72 | $54.87 |
| Resistance Level | $291.68 | $60.10 |
| Average True Range (ATR) | 9.43 | 2.13 |
| MACD | 0.03 | -0.38 |
| Stochastic Oscillator | 55.27 | 42.04 |
CSW Industrials Inc is a diversified industrial growth company with well-established, scalable platforms & domain expertise across three segments: Contractor Solutions, Engineered Building Solutions, & Specialized Reliability Solutions. The company's Contractor Solutions segment involves manufacturing efficient & performance-enhancing products for residential & commercial HVAC/R & plumbing applications, which are designed for professional end-use customers. The majority of the company's revenue is generated from the Contractor Solutions segment in the U.S. markets. products include mechanical products for heating, ventilation, air conditioning, & refrigeration, plumbing products, grilles, registers, & diffusers, building safety solutions, & high-performance specialty lubricants & sealants.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.